DnB Asset Management AS trimmed its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) by 40.1% in the second quarter, Holdings Channel.com reports. The firm owned 145,846 shares of the biotechnology company’s stock after selling 97,587 shares during the period. DnB Asset Management AS’s holdings in Aurinia Pharmaceuticals were worth $1,466,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. grew its position in shares of Aurinia Pharmaceuticals by 54.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 3,250 shares of the biotechnology company’s stock worth $40,000 after buying an additional 1,142 shares during the period. Exane Derivatives grew its position in shares of Aurinia Pharmaceuticals by 15.8% during the 1st quarter. Exane Derivatives now owns 8,683 shares of the biotechnology company’s stock worth $107,000 after buying an additional 1,182 shares during the period. Great West Life Assurance Co. Can grew its position in shares of Aurinia Pharmaceuticals by 22.3% during the 1st quarter. Great West Life Assurance Co. Can now owns 6,533 shares of the biotechnology company’s stock worth $86,000 after buying an additional 1,192 shares during the period. Ironwood Investment Management LLC grew its position in shares of Aurinia Pharmaceuticals by 1.0% during the 1st quarter. Ironwood Investment Management LLC now owns 133,117 shares of the biotechnology company’s stock worth $1,648,000 after buying an additional 1,357 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Aurinia Pharmaceuticals by 9.1% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,542 shares of the biotechnology company’s stock worth $205,000 after buying an additional 1,375 shares during the period. 35.20% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on AUPH. Oppenheimer decreased their target price on Aurinia Pharmaceuticals from $15.00 to $13.00 and set an “outperform” rating for the company in a research report on Monday, August 8th. HC Wainwright cut their price objective on Aurinia Pharmaceuticals from $30.00 to $26.00 and set a “buy” rating on the stock in a report on Tuesday, August 9th. Finally, Royal Bank of Canada cut their price objective on Aurinia Pharmaceuticals from $22.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, August 5th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $20.40.
Aurinia Pharmaceuticals Stock Performance
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) (TSE:AUP) last released its earnings results on Thursday, August 4th. The biotechnology company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.03). The firm had revenue of $28.19 million during the quarter, compared to the consensus estimate of $27.07 million. Aurinia Pharmaceuticals had a negative net margin of 178.32% and a negative return on equity of 38.01%. During the same quarter in the previous year, the firm posted ($0.37) EPS. On average, equities research analysts forecast that Aurinia Pharmaceuticals Inc. will post -0.85 EPS for the current year.
Aurinia Pharmaceuticals Profile
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.
- Get a free copy of the StockNews.com research report on Aurinia Pharmaceuticals (AUPH)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.